Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Feb;56(2):271-8.
doi: 10.1136/gut.2005.088583. Epub 2006 Jun 29.

Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model

Volker Schmitz  1 , Esther Raskopf, Maria Angeles Gonzalez-Carmona, Annabelle Vogt, Christian Rabe, Ludger Leifeld, Miroslaw Kornek, Tilman Sauerbruch, Wolfgang H Caselmann
Affiliations

Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model

Volker Schmitz et al. Gut. 2007 Feb.

Abstract

Background: The prognosis of patients with hepatocellular carcinoma (HCC) remains poor, and new alternative treatments are needed.

Aims: To comparatively test the angiostatic and antitumour effects of adenoviral gene transfer of angiostatin (PlgK1-4, amino acids 1-440) and full kringles 1-5 (PlgK1-5, amino acids 1-546) in a model of subcutaneously transferred HCC in mice.

Methods: PlgK1-4 and PlgK1-5 were generated from human WtPlg cDNA and used for adenovirus construction. Vector function and angiostatic effects were confirmed in vitro and in vivo. Antitumoral efficacies of intratumoral vector injections were studied in a model of subcutaneously transferred HCC model.

Results: Cell supernatants containing PlgK1-4 and PlgK1-5 reduced endothelial tube formation in vitro by about 30%, whereas WtPlg exerted no inhibitory effect. Endothelial cell infiltration in vivo was decreased by about 60%, but not in AdWtPlg-treated animals. Intratumoral treatment of subcutaneous HCC tumours inhibited growth by 40% for AdPlgK1-4 and 63% for AdPlgK1-5 in surviving mice 12 days after initiation of treatment, whereas treatment with AdWtPlg even led to accelerated growth. Although PlgK1-4 and PlgK1-5 have similar inhibitory effects on intratumoral microvessels, PlgK1-5 markedly improved the survival time compared with PlgK1-4.

Conclusion: PlgK1-5 and PlgK1-4 effectively inhibited HCC growth. As PlgK1-5 could also prolong the survival time, inducing complete tumour elimination in half of the AdPlgK1-5-treated mice, PlgK1-5 might be the most potential plasminogen fragment for treatment of experimental HCC.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

References

    1. Uematsu S, Higashi T, Nouso K.et al Altered expression of vascular endothelial growth factor, fibroblast growth factor‐2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 200520583–588. - PubMed
    1. Cui J, Dong B W, Liang P.et al Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma. World J Gastroenterol 2005113027–3033. - PMC - PubMed
    1. Carr B I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004127(Suppl 1)S218–S224. - PubMed
    1. Ishikawa H, Nakao K, Matsumoto K.et al Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 200337696–704. - PubMed
    1. Raskopf E, Dzienisowicz C, Hilbert T.et al Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology 2005411233–1240. - PubMed

Publication types

MeSH terms